Antibiotics for anthrax: Patient requests and physician prescribing practices during the 2001 New York City attacks

Archives of Internal Medicine

Volumn 164, Issue 18, 2004, Pages 2012-2016

  Hupert, Nathaniel ^a   Chege, Wairimu ^b   Bearman, Gonzalo M L ^c   Pelzman, Fred N ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DOXYCYCLINE;

ANTHRAX; BIOLOGICAL WARFARE; COMMUNITY; CONFIDENCE INTERVAL; ELECTRONIC MEDICAL RECORD; HUMAN; MEDICAL PRACTICE; OUTPATIENT; PHYSICAL EXAMINATION; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; REVIEW; RISK; SMALLPOX; SYMPTOM; TELEPHONE; UNITED STATES; WORKPLACE;

ADULT; AGED; AGED, 80 AND OVER; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BIOTERRORISM; CIPROFLOXACIN; DOXYCYCLINE; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 6344281152     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.18.2012     Document Type: Review

References (23)

1. Update: investigation of bioterrorism-related anthrax, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:1008-1010.
2. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019-1028.
3. Traeger MS, Wiersma ST, Rosenstein NE, et al. First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001. Emerg Infect Dis. 2002;8:1029-1034.
4. Greene CM, Reefhuis J, Tan C, et al. Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg Infect Dis. 2002;8:1048-1055.
5. Dewan PK, Fry AM, Laserson K, et al. Inhalational anthrax outbreak among postal workers, Washington, DC, 2001. Emerg Infect Dis. 2002;8:1066-1072.
6. Williams AA, Parashar UD, Stoica A, et al. Bioterrorism-related anthrax surveillance, Connecticut, September-December, 2001. Emerg Infect Dis. 2002;8:1078-1082.
7. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep. 2001;50:973-976.
8. Office of Public Health Preparedness, Centers for Disease Control and Prevention. Optimizing Post-exposure Prevention of Inhalational Anthrax: Issues and Options. Washington, DC: National Academy of Sciences, National Institutes of Health; 2001.
9. Haffer AS, Rogers JR, Montello MJ, Frank EC, Ostroff C. 2001 Anthrax crisis in Washington, DC: clinic for persons exposed to contaminated mail. Am J Health Syst Pharm. 2002;59:1189-1192.
10. Montello MJ, Ostroff C, Frank EC, Haffer AS, Rogers JR. 2001 Anthrax crisis in Washington, DC: pharmacists' role in screening patients and selecting prophylaxis. Am J Health Syst Pharm. 2002;59:1193-1199.
11. Perkins BA, Popovic T, Yeskey K. Public health in the time of bioterrorism. Emerg Infect Dis. 2002;8:1015-1018.
12. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124-1132.
13. Williams JL, Noviello SS, Griffith KS, et al. Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001. Emerg Infect Dis. 2002;8:1133-1137.
14. Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001. Emerg Infect Dis. 2002;8:1138-1144.
15. Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis. 2002;35:851-858.
16. Vlahov D, Galea S, Frankel D. New York City, 2001: reaction and response. J Urban Health. 2002;79:2-5.
17. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287:2236-2252.
18. Hupert N, Bearman GML, Callahan MA, Mushlin AI. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med. 2003;139:337-342.
19. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:984-986.
20. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909-914.
21. Gerberding JL, Hughes JM, Koplan JP. Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. JAMA. 2002;287:898-900.
22. Partridge R, Alexander J, Lawrence T, Suner S. Medical counterbioterrorism:the response to provide anthrax prophylaxis to New York City US Postal Service employees. Ann Emerg Med. 2003;41:441-446.
23. Hupert N, Mushlin AI, Callahan MA. Modeling the public health response to bioterrorism: using discrete event simulation to design antibiotic distribution centers. Med Decis Making. 2002;22(suppl 5):S17-S25.